First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Active, not recruiting · NCT03319628 · Registry updated 2023-11-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Non Small Cell Lung Cancer Metastatic; Platinum Resistant Ovarian Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2023-11-13 | NCT03319628 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mersana Therapeutics | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Oklahoma | Oklahoma City | United States | 28 |